UBS Group
SLN

UBS Group’s Silence Therapeutics SLN Stock Holding History

UBS Group’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Buy
246,937
+39,424
+19% +$217K ﹤0.01% 5341
2025
Q4 		$1.26M Sell
207,513
-99,850
-32% -$639K ﹤0.01% 5383
2025
Q3 		$1.6M Buy
307,363
+78,854
+35% +$438K ﹤0.01% 5174
2025
Q2 		$1.33M Sell
228,509
-91,005
-28% -$390K ﹤0.01% 5195
2025
Q1 		$901K Sell
319,514
-36,557
-10% -$179K ﹤0.01% 5370
2024
Q4 		$2.45M Buy
356,071
+285,410
+404% +$3.68M ﹤0.01% 4535
2024
Q3 		$1.28M Sell
70,661
-3,145
-4% -$58.5K ﹤0.01% 4418
2024
Q2 		$1.4M Buy
73,806
+1,888
+3% +$40.1K ﹤0.01% 4109
2024
Q1 		$1.55M Buy
71,918
+1,972
+3% +$42.9K ﹤0.01% 4194
2023
Q4 		$1.21M Buy
69,946
+833
+1% +$9.35K ﹤0.01% 4333
2023
Q3 		$679K Sell
69,113
-1,017
-1% -$7.5K ﹤0.01% 4412
2023
Q2 		$386K Buy
70,130
+1,124
+2% +$6.78K ﹤0.01% 5039
2023
Q1 		$428K Hold
69,006
– – ﹤0.01% 4810
2022
Q4 		$1.05M Buy
69,006
+3,191
+5% +$41.8K ﹤0.01% 4028
2022
Q3 		$660K Sell
65,815
-3,440
-5% -$36.2K ﹤0.01% 4105
2022
Q2 		$821K Sell
69,255
-113
-0.2% -$1.37K ﹤0.01% 3886
2022
Q1 		$1.32M Sell
69,368
-850
-1% -$16.9K ﹤0.01% 3835
2021
Q4 		$1.68M Buy
+70,218
New +$1.63M ﹤0.01% 3901
2021
Q1 		– Sell
-93
Closed -$2K – 9421
2020
Q4 		$2K Buy
+93
New +$1.67K ﹤0.01% 8114

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

UBS Group's SLN Position: Q1 2026 in Review

UBS Group increased its Silence Therapeutics (SLN) stake by 19% in Q1 2026, buying an estimated $217K and bringing the position to 246,937 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #5341.

UBS Group first reported a position in SLN in Q4 2020 and has held it in 19 quarters since. The position peaked at $2.45M in Q4 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • UBS Group held 246,937 shares of Silence Therapeutics worth $1.3M as of Q1 2026.
  • UBS Group bought 39,424 Silence Therapeutics shares in Q1 2026, an estimated $217K.
  • Silence Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5341 holding.
  • UBS Group first reported a position in Silence Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • UBS Group's Silence Therapeutics position peaked at $2.45M in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.